Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/15727
Full metadata record
DC FieldValue
dc.contributor.authorMarek, Martin
dc.contributor.authorOliveira, Guilherme Correa de
dc.contributor.authorPierce, Raymond J
dc.contributor.authorJung, Manfred
dc.contributor.authorSippl, Wolfgang
dc.contributor.authorRomier, Christophe
dc.date.accessioned2016-09-08T17:12:37Z
dc.date.available2016-09-08T17:12:37Z
dc.date.issued2015
dc.identifier.citationMAREK, Martin et al. Drugging the schistosome zinc-dependent HDACs: current progress and future perspectives. Future Med Chem., Vol. 7, n. 6, p.783-800, 2015
dc.identifier.issn1756-8919
dc.identifier.urihttps://www.arca.fiocruz.br/handle/icict/15727
dc.language.isopor
dc.publisherFuture Science
dc.rightsopen access
dc.titleDrugging the schistosome zinc-dependent HDACs: current progress and future perspectives.
dc.typeArticle
dc.identifier.doi10.4155/fmc.15.25
dc.description.abstractenSchistosomes, like many eukaryotic pathogens, typically display morphologically distinct stages during their life cycles. Epigenetic mechanisms underlie the pathogens' morphological transformations, and the targeting of epigenetics-driven cellular programs therefore represents an Achilles' heel of parasites. To speed up the search for new antiparasitic agents, drugs validated for other diseases can be rationally optimized into antiparasitic therapeutics. Specifically, zinc-dependent histone deacetylases (HDACs) are the most explored targets for epigenetic therapies, notably for anticancer treatments. This review focuses on the development of drug-leads inhibiting HDACs from schistosomes. More precisely, current progress on Schistosoma mansoni HDAC8 (smHDAC8) provided a proof of concept that targeting epigenetic enzymes is a valid approach to treat diseases caused by schistosomes, and possibly other eukaryotic pathogens
dc.creator.affilliationUniversité de Strasbourg . Institut de Génétique et Biologie Moléculaire et Cellulaire. Département de Biologie Structurale Intégrative. Lille Cedex, France
dc.creator.affilliationFundação Oswaldo Cruz. Centro de Pesquisas René Rachou. Grupo de Genomica e Biologia Computacional. Belo Horizonte, MG, Brasil
dc.creator.affilliationUniversité de Lille. Institut Pasteur de Lille.Center for Infection & Immunity of Lille.Lille Cedex, France
dc.creator.affilliationAlbert-Ludwigs-Universität Freiburg.Institute of Pharmaceutical Sciences. Freiburg, Germany
dc.creator.affilliationMartin-Luther-Universität Halle-Wittenberg. Institute of Pharmacy. Wolfgang-Langenbeck, Germany
dc.creator.affilliationUniversité de Strasbourg . Institut de Génétique et Biologie Moléculaire et Cellulaire. Département de Biologie Structurale Intégrative. Lille Cedex, France
dc.subject.enAnthelmintics/chemistry
dc.subject.enHelminth Proteins/antagonists & inhibitors
dc.subject.enSchistosoma/drug effects
Appears in Collections:MG - IRR - Artigos de Periódicos

Files in This Item:
File Description SizeFormat 
fmc.15.pdf11.02 MBAdobe PDFView/Open



FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.